WESTLAKE, Texas--(BUSINESS WIRE)--Heart Test Laboratories, Inc. (“HTL”) is pleased to announce the successful completion of its private placement offering. HTL has previously raised over $10 million in funding for the research and development of its MyoVista™ heart disease screening device. This latest round of funding provides the capital to complete the version of the MyoVista™ which will be sold commercially and also provides additional capital for further clinical testing. Over the past year HTL has transitioned from a research and development based company to a commercial entity, including bringing in seasoned operational leadership. HTL will be hiring additional engineering and operational staff in order to prepare for rapid growth when the product is released to the market in late 2015.
About Heart Test Laboratories Inc.
Heart Test Laboratories is a U.S. based medical device company that focuses on manufacturing devices that significantly improve screening for Coronary Arterial Disease and other cardiac based abnormalities. Heart Test Lab’s primary product is the patented MyoVista™ System. The MyoVista™ is a technology breakthrough in providing electrophysiology based testing that offers significant advantages in the early identification of ischemic and other heart abnormalities by determining the presence and level of myocardial distress. The MyoVista™ system will enable for the first time effective wide scale screening for heart disease. The process involves a short 10 minute, at rest noninvasive test. The device is simple to use and very easy for the non-specialist to interpret, with a rapid learning curve of less than two hours and includes the standard functions of a 12 lead ECG system. Heart Disease is the number one cause of death globally, and the largest area of health care expense in the United States. The MyoVista™ is positioned at the leading edge of technology advancement in the field of electrophysiology.